Skip to main content
Tara Gregory, MD, Oncology, Denver, CO

TaraGregoryMD

Oncology Denver, CO

Colorado Blood Cancer Institute

Overview of Dr. Gregory

Tara Gregory, MD, is a board-certified, fellowship-trained medical oncologist with a focus on plasma cell diseases such as multiple myeloma, amyloidosis, monoclonal gammopathies and plasma cell leukemia. Fluent in both English and Spanish, Dr. Gregory is passionate about educating patients to ensure they understand their disease and working in partnership with patients to make treatment decisions that honor quality of life as well as outcomes.
Dr. Gregory earned her Bachelor of Arts summa cum laude in Hispanic Linguistics and her honors thesis focused on the critical age of learning and brain plasticity. She also received her Bachelor of Science in molecular and cellular biology summa cum laude and wrote her honors thesis on the expression of iNOS in mouse cardiac transplant grafts. She then graduated from the University of Arizona School of Medicine in Tucson, AZ and did a residency in internal medicine at the Banner Good Samaritan/Carl T. Hayden VAMC program. Dr. Gregory then moved to Denver, CO to complete her medical oncology fellowship at the University of Colorado. After finishing the fellowship, Dr. Gregory was the first blood and marrow transplant fellow at CBCI. Today, Dr. Gregory is the co-director of the Plasma Cell Dyscrasia Program at CBCI focusing on diseases such as multiple myeloma, amyloidosis, monoclonal gammopathies and plasma cell leukemia. The focus of her research work is in multiple myeloma treatments including chimeric antigen T cell therapy.
Dr. Gregory is a member of several societies, including the International Myeloma Society, American Society of Hematology, the American Society of Clinical Oncology and the American Society for Blood and Marrow Transplantation. She actively participates in clinical trials including research in blood and marrow transplant outcomes, the results which have been presented at multiple research meetings.

Education & Training

  • University of Colorado
    University of ColoradoFellowship, Hematology and Medical Oncology, 2007 - 2009
  • University of Arizona College of Medicine-Phoenix
    University of Arizona College of Medicine-PhoenixResidency, Internal Medicine, 2004 - 2007
  • University of Arizona College of Medicine
    University of Arizona College of MedicineClass of 2004

Certifications & Licensure

  • CO State Medical License
    CO State Medical License 2008 - 2025
  • NM State Medical License
    NM State Medical License 2013 - 2022
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Ma...
    Tara K. Gregory, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with ...
    Tara K. Gregory, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)Clinically Relevant Abstract
    Tara K. Gregory, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • CAR T-cell Therapies Targeting CD20 Show Early Potential to Prevent, Mitigate NHL Relapse
    CAR T-cell Therapies Targeting CD20 Show Early Potential to Prevent, Mitigate NHL RelapseJune 8th, 2021
  • Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO® Annual Meeting
    Sarah Cannon to Present Latest Cancer Research Insights at 2021 ASCO® Annual MeetingJune 4th, 2021

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    Anthem KeyCare PPO
    Anthem PPO
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Cofinity PPO
    First Health PPO
    Great West PPO
    Humana ChoiceCare Network PPO
    Multiplan PHCS PPO
    Multiplan PPO
    Rocky Mountain Group/Indiv - HMO/Private Pay
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment